Deciphering the melanoma interactome

Journal of Cutaneous Pathology

Volumn 35, Issue SUPPL. 2, 2008, Pages 11-15

  Reed, Jon A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE;

CANCER CELL; CANCER STAGING; CELL INTERACTION; DISEASE COURSE; ELECTRON MICROSCOPE; EPIGENETICS; HUMAN; MELANOMA; MOLECULAR GENETICS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

HUMANS; MELANOCYTES; MELANOMA; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 54149099996     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2008.01119.x     Document Type: Review

References (47)

1. Lopez-Bergami P, Fitchman B, Ronai Z. Understanding signaling cascades in melanoma. Photochem Photobiol 2008 84 : 289.
2. Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V. Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 2006 12 (7 Pt 2 2301s.
3. Haluska F, Pemberton T, Ibrahim N, Kalinsky K. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications. Semin Oncol 2007 34 : 546.
4. Medrano EE. Wnt5a and PKC, a deadly partnership involved in melanoma invasion. Pigment Cell Res 2007 20 : 258.
5. Reed JA, Medrano EE. Recent advances in melanoma research. Front Biosci 2006 11 : 3003.
6. Delmas V, Beermann F, Martinozzi S, et al. Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev 2007 21 : 2923.
7. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002 417 : 949.
8. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002 62 : 6997.
9. Kaufmann WK, Nevis KR, Qu P, et al. Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression. J Invest Dermatol 2008 128 : 175.
10. Meier F, Busch S, Lasithiotakis K, et al. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol 2007 156 : 1204.
11. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 2006 95 : 581.
12. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003 33 : 19.
13. Dumaz N, Hayward R, Martin J, et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 2006 66 : 9483.
14. Soballe PW, M Herlyn. Cellular pathways leading to melanoma differentiation: therapeutic implications. Melanoma Res 1994 4 : 213.
15. Mani KM, Lefebvre C, Wang K, et al. A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas. Mol Syst Biol 2008 4 : 169.
16. Jonsson PF, Bates PA. Global topological features of cancer proteins in the human interactome. Bioinformatics 2006 22 : 2291.
17. Hernandez P, Huerta-Cepas J, Montaner D, et al. Evidence for systems-level molecular mechanisms of tumorigenesis. BMC Genomics 2007 8 : 185.
18. Goh Kl, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL. The human disease network. Proc Natl Acad Sci U S A 2007 104 : 8685.
19. Reed JA, Lin Q, Chen D, Mian IS, Medrano EE. SKI pathways inducing progression of human melanoma. Cancer Metastasis Rev 2005 24 : 265.
20. Fumagalli S, Doneda L, Nomura N, Larizza L. Expression of the c-ski proto-oncogene in human melanoma cell lines. Melanoma Res 1993 3 : 23.
21. Reed JA, Bales E, Xu W, Okan NA, Bandyopadhyay D, Medrano EE. Cytoplasmic localization of the oncogenic protein Ski in human cutaneous melanomas in vivo: functional implications for transforming growth factor beta signaling. Cancer Res 2001 61 : 8074.
22. Xu W, Angelis K, Danielpour D, et al. Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type beta transforming growth factor. Proc Natl Acad Sci U S A 2000 97 : 5924.
23. Hussein MR. Transforming growth factor-beta and malignant melanoma: molecular mechanisms. J Cutan Pathol 2005 32 : 389.
24. Medrano EE. Repression of TGF-beta signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival, and metastasis. Oncogene 2003 22 : 3123.
25. Chen D, Xu W, Bales E, et al. SKI activates Wnt/beta-catenin signaling in human melanoma. Cancer Res 2003 63 : 6626.
26. Demirkan NC, Kesen Z, Akdag B, Larue L, Delmas V. The effect of the sun on expression of beta-catenin, p16 and cyclin d1 proteins in melanocytic lesions. Clin Exp Dermatol 2007 32 : 733.
27. Larue L, Delmas V. The WNT/Beta-catenin pathway in melanoma. Front Biosci 2006 11 : 733.
28. Beebe SJ, Salomonsky P, Holroyd C, Becker D. Differential expression of cyclic AMP-dependent protein kinase isozymes in normal human melanocytes and malignant melanomas. Cell Growth Differ 1993 4 : 1005.
29. Bennett DC, Medrano EE. Molecular regulation of melanocyte senescence. Pigment Cell Res 2002 15 : 242.
30. Burns LL, Canaves JM, Pennypacker JK, Blumenthal DK, Taylor SS. Isoform specific differences in binding of a dual-specificity A-kinase anchoring protein to type I and type II regulatory subunits of PKA. Biochemistry 2003 42 : 5754.
31. Neary CL, Nesterova M, Cho YS, Cheadle C, Becker KG, Cho-Chung YS. Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion. Oncogene 2004 23 : 8847.
32. Mantovani G, Bondioni S, Lania AG, et al. High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells. Oncogene 2008 27 : 1834.
33. Martins SB, Eide T, Steen RL, Jahnsen T, Skalhegg BS, Collas P. HA95 is a protein of the chromatin and nuclear matrix regulating nuclear envelope dynamics. J Cell Sci 2000 113 (Pt 21 3703.
34. Landsverk HB, Carlson CR, Steen RL, et al. Regulation of anchoring of the RIIalpha regulatory subunit of PKA to AKAP95 by threonine phosphorylation of RIIalpha: implications for chromosome dynamics at mitosis. J Cell Sci 2001 114 (Pt 18 3255.
35. Arsenijevic T, Degraef C, Dumont JE, Roger PP, Pirson I. G1/S Cyclins interact with regulatory subunit of PKA via A-kinase anchoring protein, AKAP95. Cell Cycle 2006 5 : 1217.
36. Bales E, Mills L, Milam N, et al. The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res 2005 65 : 692.
37. Brena RM, Costello JF. Genome-epigenome interactions in cancer. Hum Mol Genet 2007 16 : R96.
38. Weber M, Hellmann I, Stadler MB, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007 39 : 457.
39. Rothhammer T, Bosserhoff AK. Epigenetic events in malignant melanoma. Pigment Cell Res 2007 20 : 92.
40. Bandyopadhyay D, Mishra A, Medrano EE. Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res 2004 64 : 7706.
41. Dahl C, Guldberg P. The genome and epigenome of malignant melanoma. APMIS 2007 115 : 1161.
42. Bandyopadhyay D, Okan NA, Bales E, Nascimento L, Cole PA, Medrano EE. Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Cancer Res 2002 62 : 6231.
43. Bandyopadhyay D, Curry JL, Lin Q, et al. Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi. Aging Cell 2007 6 : 577.
44. Reed JA, Loganzo F, Jr., Shea CR, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995 55 : 2713.
45. Straume O, Smeds J, Kumar R, Hemminki K, Akslen LA. Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol 2002 161 : 229.
46. Reed JA, Manahan LJ, Park CS, Brigati DJ. Complete one-hour immunocytochemistry based on capillary action. Biotechniques 1992 13 : 434.
47. Gilhooly EM, Morse-Gaudio M, et al. Loss of expression of protein kinase C beta is a common phenomenon in human malignant melanoma: a result of transformation or differentiation? Melanoma Res 2001 11 : 355.